Competition in the DNA sequencing market is heating up. Life Technologies
None of it seems to be affecting Illumina's
Getting machines out to customers quickly is important, not just to get into the market before Life Tech has captured it, but also because the machines consume reagents that Illumina sells. The faster the machines are installed, the faster the ramp up in consumables can occur.
The increase in revenue clearly helped Illumina, as selling, general and administrative expense dropped from 26.2% of revenue last year to just 23.3% of revenue this year. Total operating profit increased more than 80%, even with some substantial one-time charges.
While that's outstanding, investors should keep an eye on Illumina's research and development expenses, which only increased 15% year over year. Research and development spending needs to continue growing – otherwise, Illumina will just shoot itself in the proverbial long-term foot. Illumina must innovate or expect to be passed by in this competitive business. Fortunately, management doesn't sound like they're planning on decreasing research as a percent of revenue any further.
Pacific Biosciences of California is a Motley Fool Rule Breakers choice. Illumina is a Motley Fool Stock Advisor selection. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Motley Fool has a disclosure policy.